Suchen
Schrodinger Inc
SDGRZur Watchlist hinzufügen
12.690USD
-0.030-0.24%
Handelsschluss 05/12, 16:00（ET）Kurse um 15 Minuten verzögert
948.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Schrodinger Inc Unternehmen
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Schrodinger Inc Informationen
BörsenkürzelSDGR
Name des UnternehmensSchrodinger Inc
IPO-datumFeb 06, 2020
CEOFarid (Ramy Farid)
Anzahl der mitarbeiter891
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse1540 Broadway
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10036
Telefon15032991150
Websitehttps://www.schrodinger.com
BörsenkürzelSDGR
IPO-datumFeb 06, 2020
CEOFarid (Ramy Farid)
Führungskräfte von Schrodinger Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.40M
+0.19%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
72.66K
+50.36%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.68%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
11.25K
-8.86%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
11.25K
-8.86%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
10.49K
-402.13%
Ms. Bridget Anne Van Kralingen
Ms. Bridget Anne Van Kralingen
Independent Director
Independent Director
3.33K
-245.00%
Dr. Ramy Farid, Ph.D.
Dr. Ramy Farid, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Robert Abel, Ph.D.
Dr. Robert Abel, Ph.D.
Executive Vice President, Chief Scientific Officer, Platform
Executive Vice President, Chief Scientific Officer, Platform
--
--
Dr. Karen Akinsanya, Ph.D.
Dr. Karen Akinsanya, Ph.D.
President - R&D Therapeutics
President - R&D Therapeutics
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Richard A. Friesner, Ph.D.
Dr. Richard A. Friesner, Ph.D.
Director
Director
1.40M
+0.19%
Mr. Kenneth Patrick (Patrick) Lorton
Mr. Kenneth Patrick (Patrick) Lorton
Executive Vice President, Chief Operating Officer - Software
Executive Vice President, Chief Operating Officer - Software
72.66K
+50.36%
Ms. Margaret Dugan, M.D.
Ms. Margaret Dugan, M.D.
Chief Medical Officer
Chief Medical Officer
24.57K
-5.68%
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Dr. Rosana Kapeller-Libermann, M.D., Ph.D.
Independent Director
Independent Director
11.25K
-8.86%
Mr. Arun Oberoi
Mr. Arun Oberoi
Independent Director
Independent Director
11.25K
-8.86%
Ms. Yvonne Tran, J.D.
Ms. Yvonne Tran, J.D.
Chief People Officer, Executive Vice President, Chief Legal Officer
Chief People Officer, Executive Vice President, Chief Legal Officer
10.49K
-402.13%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Apr 6
Währung: USDAktualisiert: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
On-premise software
101.45M
39.65%
Drug discovery services
54.76M
21.40%
Hosted software
45.12M
17.64%
Software maintenance
27.29M
10.67%
Contribution
15.99M
6.25%
Andere
11.26M
4.40%
Nach RegionUSD
Name
Umsatz
Anteil
United States
152.96M
59.78%
EMEA
75.16M
29.38%
APAC
26.18M
10.23%
Rest of World
1.56M
0.61%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
On-premise software
101.45M
39.65%
Drug discovery services
54.76M
21.40%
Hosted software
45.12M
17.64%
Software maintenance
27.29M
10.67%
Contribution
15.99M
6.25%
Andere
11.26M
4.40%
Aktionärsstatistik
Aktualisiert: Mon, May 11
Aktualisiert: Mon, May 11
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.36%
Bill & Melinda Gates Foundation Trust
10.65%
Rubric Capital Management LP
6.36%
Vanguard Portfolio Management, LLC
5.89%
Amova Asset Management Co., Ltd.
4.87%
Andere
59.87%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
12.36%
Bill & Melinda Gates Foundation Trust
10.65%
Rubric Capital Management LP
6.36%
Vanguard Portfolio Management, LLC
5.89%
Amova Asset Management Co., Ltd.
4.87%
Andere
59.87%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
42.81%
Investment Advisor/Hedge Fund
26.30%
Hedge Fund
12.61%
Endowment Fund
10.65%
Individual Investor
3.00%
Research Firm
2.77%
Bank and Trust
2.11%
Pension Fund
0.76%
Private Equity
0.31%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
525
71.93M
109.89%
-7.22M
2025Q4
534
70.89M
109.90%
-7.48M
2025Q3
545
71.77M
111.28%
-2.08M
2025Q2
572
66.46M
103.14%
-5.60M
2025Q1
593
67.21M
104.69%
-5.43M
2024Q4
576
64.44M
100.89%
-9.04M
2024Q3
581
67.44M
105.91%
-6.15M
2024Q2
573
64.76M
101.80%
-8.12M
2024Q1
574
63.48M
100.05%
-5.40M
2023Q4
584
62.06M
98.56%
-7.64M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
8.10M
12.53%
+9.48K
+0.12%
Dec 31, 2025
Bill & Melinda Gates Foundation Trust
6.98M
10.8%
--
--
Dec 31, 2025
Rubric Capital Management LP
4.17M
6.45%
-1.10M
-20.83%
Dec 31, 2025
Amova Asset Management Co., Ltd.
4.71M
7.29%
+160.20K
+3.52%
Dec 31, 2025
MFS Investment Management
2.29M
3.54%
+218.92K
+10.56%
Dec 31, 2025
Lazard Asset Management, L.L.C.
2.13M
3.3%
-211.47K
-9.01%
Dec 31, 2025
State Street Investment Management (US)
2.13M
3.3%
-73.13K
-3.32%
Dec 31, 2025
ARK Investment Management LLC
2.11M
3.27%
+239.15K
+12.77%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
ARK Genomic Revolution ETF
3.63%
Clough Select Equity ETF
3.12%
TrueShares Technology, AI & Deep Learning ETF
1.99%
Global X HealthTech ETF
1.14%
State Street SPDR FactSet Innovative Technolgy ETF
0.84%
Franklin Exponential Data ETF
0.82%
WisdomTree BioRevolution Fund
0.77%
Invesco S&P SmallCap Health Care ETF
0.72%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.47%
First Trust Multi-Manager Small Cap Opportunities ETF
0.47%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil3.63%
Clough Select Equity ETF
Anteil3.12%
TrueShares Technology, AI & Deep Learning ETF
Anteil1.99%
Global X HealthTech ETF
Anteil1.14%
State Street SPDR FactSet Innovative Technolgy ETF
Anteil0.84%
Franklin Exponential Data ETF
Anteil0.82%
WisdomTree BioRevolution Fund
Anteil0.77%
Invesco S&P SmallCap Health Care ETF
Anteil0.72%
First Trust Nasdaq Lux Digi Health Solutions ETF
Anteil0.47%
First Trust Multi-Manager Small Cap Opportunities ETF
Anteil0.47%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
